niacin/inflammation

The present invention concerns the use of a vitamin combination for the treatment of pruritus and non-infective disorders involving itching and/or inflammation. More particularly, this invention relates to the use of a combination of two vitamin compounds, i.e. riboflavin (also known as vitamin

SPECIFICATION The present invention concerns the use of a vitamin combination for the treatment of pruritus and non-infective disorders involving itching and/or inflammation. More particularly, this invention relates to the use of a combination of two vitamin compounds, i.e. riboflavin (also known

The invention is related to nutritional, pharmaceutical or dietetic preparations that comprise ribose or folic acid or functional analogs thereof and the use of these compositions in the prevention or treatment of specific diseases that are related to disorders or insufficiencies of total nucleotide

The invention is related to nutritional, pharmaceutical, or dietetic preparations that comprise ribose or folic acid or functional analogs thereof and the use of these compositions in the prevention or treatment of specific diseases that are related to disorders or insufficient of total nucleotide

FIELD OF THE INVENTION This invention relates to a method and kit for inhibiting and/or reducing the incidence and effect of insect bites. More particularly, the method and kit of this invention can be used to inhibit mosquitoes from biting a subject and can be used to reduce swelling, inflammation

TECHNICAL FIELD This invention describes a nutritional composition and method of use for prevention of Parkinson's disease, therefore relating to the fields of nutrition, pharmacology, neurology, pathophysiology, medicine and movement disorders. DESCRIPTION OF THE RELATED ART Parkinson's disease

I. FIELD OF THE INVENTION The invention concerns methods and compositions for administration of antihyperlipidemic (ie., hypolipemic or antilipemic) drugs, particularly nicotinic acid and its derivatives, while producing decreased flushing reaction. II. BACKGROUND Abnormally high levels of

BACKGROUND OF THE INVENTION This invention relates to a composition and method of manufacture and use in which xanthan gum is combined with an active pharmaceutical or other ingredient in a compacted dose form for delivering the active ingredient to the gastro-intestinal tract over a sustained

This invention relates to a composition and method of manufacture and use in which xanthan gum is combined with an active pharmaceutical or other ingredient in a compacted dose form for delivering the active ingredient to the gastro-intestinal tract over a sustained period. Sustained or slow release

FIELD OF INVENTION The present invention generally relates to systems, apparatus and methods for removing lipids from HDL particles while leaving LDL particles substantially intact, via the extracorporeal treatment of blood plasma using either a single solvent or multiple solvents. The method of the

FIELD OF INVENTION The present invention generally relates to systems, apparatus and methods for removing lipids from HDL particles while leaving LDL particles substantially intact, via the extracorporeal treatment of blood plasma using either a single solvent or multiple solvents. The method of the

FIELD OF INVENTION The present invention generally relates to systems, apparatus and methods for removing lipids from HDL particles while leaving LDL particles substantially intact, via the extracorporeal treatment of blood plasma using either a single solvent or multiple solvents. The method of the

FIELD OF INVENTION The present invention generally relates to systems, apparatus and methods for removing lipids from HDL particles while leaving LDL particles substantially intact, via the extracorporeal treatment of blood plasma using either a single solvent or multiple solvents. The method of the

FIELD OF INVENTION The present invention generally relates to systems, apparatus and methods for removing lipids from HDL particles while leaving LDL particles substantially intact, via the extracorporeal treatment of blood plasma using either a single solvent or multiple solvents. The method of the